Advanced Science (Jul 2022)

Targeting mTORC2/HDAC3 Inhibits Stemness of Liver Cancer Cells Against Glutamine Starvation

  • Hui‐Lu Zhang,
  • Ping Chen,
  • He‐Xin Yan,
  • Gong‐Bo Fu,
  • Fei‐Fei Luo,
  • Jun Zhang,
  • Shi‐Min Zhao,
  • Bo Zhai,
  • Jiang‐Hong Yu,
  • Lin Chen,
  • Hao‐Shu Cui,
  • Jian Chen,
  • Shuai Huang,
  • Jun Zeng,
  • Wei Xu,
  • Hong‐Yang Wang,
  • Jie Liu

DOI
https://doi.org/10.1002/advs.202103887
Journal volume & issue
Vol. 9, no. 20
pp. n/a – n/a

Abstract

Read online

Abstract Cancer cells are addicted to glutamine. However, cancer cells often suffer from glutamine starvation, which largely results from the fast growth of cancer cells and the insufficient vascularization in the interior of cancer tissues. Herein, based on clinical samples, patient‐derived cells (PDCs), and cell lines, it is found that liver cancer cells display stem‐like characteristics upon glutamine shortage due to maintaining the stemness of tumor initiating cells (TICs) and even promoting transformation of non‐TICs into stem‐like cells by glutamine starvation. Increased expression of glutamine synthetase (GS) is essential for maintaining and promoting stem‐like characteristics of liver cancer cells during glutamine starvation. Mechanistically, glutamine starvation activates Rictor/mTORC2 to induce HDAC3‐mediated deacetylation and stabilization of GS. Rictor is significantly correlated with the expression of GS and stem marker OCT4 at tumor site, and closely correlates with poor prognosis of hepatocellular carcinomas. Inhibiting components of mTORC2‐HDAC3‐GS axis decrease TICs and promote xenografts regression upon glutamine‐starvation therapy. Collectively, the data provides novel insights into the role of Rictor/mTORC2‐HDAC3 in reprogramming glutamine metabolism to sustain stemness of cancer cells. Targeting Rictor/HDAC3 may enhance the efficacy of glutamine‐starvation therapy and limit the rapid growth and malignant progression of tumors.

Keywords